Cardiometabolic Articles & Analysis
9 news found
Lumen's clinical pipeline includes investigational biologic drugs for C. difficile infection, Covid-19, cardiometabolic disease, inflammatory bowel disease, norovirus, and traveler's diarrhea. ...
About INV-202 INV-202 is a small molecule CB1 inverse agonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including diabetic kidney disease. ...
Lumen’s pipeline is primarily focused on commercial targets, including collaborations with Novo Nordisk (in obesity and cardiometabolic disease) and Kyorin Pharmaceuticals (specific targets not yet disclosed). ...
Such a study presents an opportunity to evaluate a comprehensive set of biomarker data in DKD that may also be relevant to a broad landscape of diabetic-related indications, including cardiometabolic and fibrotic complications. INV-202, which is presently completing Phase 1b studies in patients with metabolic syndrome, showed a favorable profile in a first-in-human study, ...
“These messages include DNA, RNA, protein and lipid biomarkers found in blood (or other biofluids) that have important applications in research, diagnosis and treatment for cancer, as well as cardiometabolic diseases like heart attack and diabetes, inflammatory diseases such as rheumatoid arthritis and Crohn’s disease, and neurodegenerative diseases like ...
” Beyond campylobacter, Lumen is currently applying the technology to a growing list of highly prevalent diseases, including the following publicly disclosed programs: LMN-201, a complex biologic cocktail for prevention of C. difficile infection (in collaboration with National Institute of Allergy and Infectious Diseases (NIAID) and Rockefeller University) LMN-301, an antibody cocktail ...
” In 2018, Dicerna and Lilly announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new therapies for cardiometabolic disease, neurodegenerative diseases and pain. Including these two targets, there are currently seven candidates in preclinical or clinical development under the agreement that are ...
In this way, the diagnosis of GDM may be seen as identifying women who have a long-standing, high-risk cardiometabolic profile that would otherwise escape clinical detection during the relative youth of their childbearing years, if not for the screening that they undergo during pregnancy that will diagnose ...
Principal Investigator: Michele Ramsay, University of the Witwatersrand and NHLS, Johannesburg Genomic and environmental risk factors for cardiometabolic disease in Africans Wellcome Trust-funded research projects include: 7. ...